Lucid Diagnostics (LUCD) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Lucid Diagnostics

NasdaqCM•Healthcare•Medical Devices

$0.94-0.01(-0.01%)Market closed

Market Cap

$147.23M

P/S

27.0x

P/B

13.5x

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

How this company scores

WeakMetricSide Score: 46/100

Grade capped at D — Interest coverage below 1× (-3167.8x) — earnings cannot cover interest. Strongest: Growth (20/25); weakest: Cash & Earnings Quality (6/25).

Profitability13/25

Growth20/25

Balance Sheet & Red Flags7/25

Cash & Earnings Quality6/25

Strengths

Growing revenueProfit converts from growthConsistent growthNet cash position

Grade capped at D

Interest coverage below 1× (-3167.8x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 27.0x5y range 9.3x – 134.9x

Currently near its 17-quarter median.

P/B · 13.5x5y range 1.8x – 40.3x

Currently above its 17-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $147.23M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $5.45M
Q. Revenue: $1.47M
TTM EBITDA: $-49.37M
TTM Op. Income: $-50.68M
Q. Op. Income: $-12.80M
TTM Net Income: $-52.26M
Q. Net Income: $-11.69M
EPS: N/A
Shares Out.: $183.12M

$5.45M in TTM revenue grew 24.9% YoY, reaching $1.47M last quarter. TTM EBITDA of $-49.37M and TTM operating income of $-50.68M show growth is flowing through to the bottom line. However, net income is negative at $52.26M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 5 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 2.0%
EBITDA Margin: -853.3%
Op. Margin: -868.5%
Net Margin: -792.9%

Op. margin of -868.5% is up 110.4% YoY — cost efficiency is improving. Net margin at -792.9% and gross margin of 2.0% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 11% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 27.0x
P/B Ratio: 13.5x

P/S of 27.0x and P/B of 13.5x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $38.95M
Cash: $33.40M
Long-Term Debt: N/A
Book Value: $10.93M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-11.30M
TTM Free Cash Flow: $-47.30M
FCF Margin: -868.7%
FCF / Net Income: 0.9

TTM FCF of $-47.30M on $-11.30M in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 10% — a weakening trend.